Polycyclo Ring System Having The Thiazole Ring As One Of The Cyclos Patents (Class 514/366)
  • Patent number: 10081589
    Abstract: A method for manufacturing an ?-bromoacetophenone compound includes brominating a specific phenyl compound by reacting the specific phenyl compound with bromine in a solvent including at least one organic acid ester compound so as to obtain the ?-bromoacetophenone compound that is a liquid at 5° C. to 30° C.
    Type: Grant
    Filed: October 13, 2016
    Date of Patent: September 25, 2018
    Assignee: FUJIFILM Corporation
    Inventors: Katsuhiro Shimono, Katsuyuki Yofu
  • Patent number: 10072296
    Abstract: The present invention provides methods and compositions involving epigenetic and gene expression signatures and their association with Sjögren's syndrome.
    Type: Grant
    Filed: September 19, 2017
    Date of Patent: September 11, 2018
    Assignee: The Charlotte Mecklenburg Hospital Authority
    Inventors: Jean-Luc C. Mougeot, Farah K. B. Mougeot, Nirav Shah
  • Patent number: 9815852
    Abstract: The instant invention describes macrocyclic compounds having therapeutic activity, and methods of treating disorders such as cancer, tumors and cell proliferation related disorders.
    Type: Grant
    Filed: June 25, 2015
    Date of Patent: November 14, 2017
    Assignees: University of Florida Research Foundation, Incorporated, Duke University
    Inventors: Hendrik Luesch, Jiyong Hong
  • Patent number: 9464007
    Abstract: The present invention relates to, inter alia, methods for the treatment of wallboards with fungicides and the treated wallboards. In particular, the invention relates to the treatment of wallboards with a fungicidally effective amount of difenoconazole. The invention also provides for the treatment of wallboards with synergistic combinations of difenoconazole and other fungicides. The invention also provides the treatment of building materials with difenoconazole and synergistic mixtures containing difenoconazole.
    Type: Grant
    Filed: December 15, 2005
    Date of Patent: October 11, 2016
    Assignee: LANXESS Deutschland GmbH
    Inventors: Alexander Cornish, Anja Greiner, Gertrude Knauf-Beiter, Johann Steiner
  • Patent number: 9422340
    Abstract: The present invention provides a novel macrocyclic compound of general Formula (I) having histone deacetylase (HDAC) inhibitory activity, a pharmaceutical composition comprising the compound, and a method useful to treat diseases using the compound.
    Type: Grant
    Filed: May 29, 2014
    Date of Patent: August 23, 2016
    Assignee: The Regents of the University of Colorado, A Body Corporate
    Inventors: Xuedong Liu, Andrew J. Phillips, Dana Ungermannova, Christopher G. Nasveschuk, Gan Zhang
  • Publication number: 20150148308
    Abstract: A harmful arthropod control composition comprising a compound represented by the following Formula (1) wherein each symbol represents definitions described in the specification, and one or more fungicidal compounds, which are selected from among azoles, strobilurins, phenylamides, rice blast controlling compounds, rice sheath blight disease controlling compounds, and other fungicidal compounds. The composition has an excellent controlling effect against harmful arthropods.
    Type: Application
    Filed: June 5, 2013
    Publication date: May 28, 2015
    Applicant: Sumitomo Chemical Company, Limited
    Inventors: Tatsuya Suzuki, Atsushi Iwata, Yoshihiko Nokura
  • Publication number: 20150126505
    Abstract: Compounds, compositions and methods are provided for modulating the activity of receptor kinases and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder mediated by receptor kinases.
    Type: Application
    Filed: October 31, 2014
    Publication date: May 7, 2015
    Inventors: Shripad Bhagwat, Qi Chao, Robert M. Grotzfeld, Hitesh K. Patel, Kelly G. Sprankle
  • Patent number: 9023875
    Abstract: The instant invention describes macrocyclic compounds having therapeutic activity, and methods of treating disorders such as cancer, tumors and cell proliferation related disorders, or affect cell differentiation, dedifferentiation or transdifferentiation.
    Type: Grant
    Filed: January 22, 2013
    Date of Patent: May 5, 2015
    Assignee: University of Florida Research Foundation, Inc.
    Inventors: Hendrik Luesch, Taori Kanchan, Valerie J. Paul
  • Patent number: 8993604
    Abstract: Methods and pharmaceutical compositions for treating viral infections, by administering certain 2-aryl-benzothiazole or 2-heteroaryl-benzothiazole derivative compounds in therapeutically effective amounts are disclosed. Methods of using the compounds and pharmaceutical compositions thereof are also disclosed. In particular, the treatment and prophylaxis of viral infections such as caused by flavivirus is disclosed, i.e., including but not limited to, Dengue virus, West Nile virus, yellow fever virus, Japanese encephalitis virus, and tick-borne encephalitis virus.
    Type: Grant
    Filed: June 22, 2010
    Date of Patent: March 31, 2015
    Assignee: Siga Technologies, Inc.
    Inventors: Chelsea M. Byrd, Dongcheng Dai, Robert Jordan, Dennis E. Hruby
  • Patent number: 8969573
    Abstract: Compositions and methods for inhibiting translation are provided. Compositions, methods and kits for treating (1) cellular proliferative disorders, (2) non-proliferative, degenerative disorders, (3) viral infections, (4) disorders associated with viral infections, and/or (5) non-proliferative metabolic disorders such as type II diabetes where inhibition of translation initiation is beneficial using the compounds disclosed herein.
    Type: Grant
    Filed: June 28, 2011
    Date of Patent: March 3, 2015
    Assignee: President and Fellows of Harvard College
    Inventors: Michael Chorev, Bertal Huseyin Aktas, Jose A. Halperin, Gerhard Wagner
  • Patent number: 8969417
    Abstract: Pharmaceutical compositions are provided for treatment of Parkinson's disease comprising a pharmaceutically acceptable carrier and a fixed dose combination of two active agents selected from compounds having either neuroprotective or symptomatic effects, or both, in Parkinson's disease patients, wherein the molar ratio of the two compounds is in the range of 1:1 to 1:100. The compositions are formulated for immediate release, controlled release, or both immediate and controlled release.
    Type: Grant
    Filed: June 7, 2009
    Date of Patent: March 3, 2015
    Assignee: Pharmatwob Ltd.
    Inventors: Itschak Lamensdorf, Yoram Sela
  • Patent number: 8962578
    Abstract: The invention relates to novel fungicidally active compound combinations of 2?-cyano-3,4-dichloroisothiazole-5-carboxanilide and active compounds listed in the disclosure.
    Type: Grant
    Filed: March 5, 2013
    Date of Patent: February 24, 2015
    Assignee: Bayer CropScience AG
    Inventors: Peter Dahmen, Ulrike Wachendorff-Neumann, Rolf Pontzen, Lutz Assmann, Haruko Sawada
  • Publication number: 20150011528
    Abstract: Provided is a phenylimide-containing benzothiazole derivative or its pharmaceutically acceptable salt, a process for the preparation thereof, and a pharmaceutical composition comprising the same. The phenylimide-containing benzothiazole derivative or its pharmaceutically acceptable salt can selectively inhibit the protein-protein interaction between KRS and a laminin receptor (LR), thereby inhibiting migration of cancer cells. Therefore, the phenylimide-containing benzothiazole derivative or its pharmaceutically acceptable salt may be usefully applied for preventing or treating the diseases associated with cancer cell metastasis.
    Type: Application
    Filed: September 21, 2012
    Publication date: January 8, 2015
    Applicant: YUHAN CORPORATION
    Inventors: Youn Hur, Dong-Hyun Kim, Eun-Kyung Kim, Jin-Hwi Park, Jae-Eun Joo, Ho-Woong Kang, Se-Woong Oh, Dong-Kyun Kim, Kyoung-Kyu Ahn
  • Publication number: 20150010504
    Abstract: Disclosed are compounds of formula (I) for use as antiviral agents, particularly as anti-hepatitis virus C agents, wherein A, B, U, R1-R7, m, n, and q are as described herein. Also disclosed are pharmaceutical compositions and methods of treating or preventing viral infection in a host by the use of these compounds, either alone or in combination with other pharmaceutically active agents. Further disclosed are methods of preparing such compounds.
    Type: Application
    Filed: February 9, 2013
    Publication date: January 8, 2015
    Applicant: Lupin Limited
    Inventors: Vidya Ramdas, Advait Arun Joshi, Moloy Manoj Banerjee, Amit Kumar Das, Deepak Sahebrao Walke, Venkata P. Palle, Rajender Kumar Kamboj
  • Patent number: 8921320
    Abstract: A targeted osmotic lysis (TOL) of tumor cells that over-express voltage-gated sodium channels (VGSCs) has been developed that uses a combined therapy of a drug that blocks sodium, potassium-adenosine triphosphatase (Na+, K+-ATPase) that is then followed by an activation of VGSCs, for example, by electrical or pharmacological stimulation. Activation of VGSCs conducts sodium into the cancer cells in much greater amounts than non-cancer cells. Water follows this sodium gradient into the cancer cells, causing swelling and lysis. Because non-cancerous cells do not over-express VGSCs, less sodium and less water will enter the cells, and the non-cancerous cells will not lyse. This method is applicable to all cells that over-express VGSCs, including, but not limited to, highly invasive breast cancer, prostate cancer, small cell lung cancer, non-small cell lung carcinoma, lymphoma, mesothelioma, neuroblastoma, and cervical cancer.
    Type: Grant
    Filed: July 19, 2012
    Date of Patent: December 30, 2014
    Assignee: Board of Supervisors of Louisiana State University and Agricultural and Mechanical College
    Inventors: Dennis J. Paul, Harry J. Gould
  • Publication number: 20140364385
    Abstract: An isolated compound of Formula I and salts thereof are provided: wherein X is Cl or Br. A compound isolated from Actinomadura and having a chemical formula of C43H69ClN4O10S2 or C43H69BrN4O10S2 is also provided. Compositions including the compounds and methods of using the compounds to treat fungal infections including those such as Candida are also disclosed.
    Type: Application
    Filed: June 9, 2014
    Publication date: December 11, 2014
    Inventors: Timothy BUGNI, Thomas WYCHE, David ANDES, Douglas BRAUN
  • Patent number: 8901157
    Abstract: The present invention discloses compositions and a method of improving the pharmacokinetics of pharmaceutical agents (or pharmaceutically acceptable salts, esters, and prodrugs thereof) which are metabolized by cytochrome P450 monoxygenase comprising coadministering ritonavir or a pharmaceutically acceptable salt, ester, and prodrug thereof.
    Type: Grant
    Filed: December 2, 2010
    Date of Patent: December 2, 2014
    Assignee: AbbVie Inc.
    Inventors: Dale J. Kempf, Kennan C. Marsh
  • Patent number: 8895591
    Abstract: The present invention provides a compound represented by the formula which is useful as an agent for the prophylaxis or treatment of diseases related to the action of melatonin, or a salt thereof and the like.
    Type: Grant
    Filed: September 4, 2013
    Date of Patent: November 25, 2014
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Osamu Uchikawa, Tatsuki Koike, Yasutaka Hoashi, Takafumi Takai
  • Publication number: 20140336184
    Abstract: The present invention concerns methods and compositions regarding suppression of double stranded RNA-activated protein kinase (PKR) to enhance cognition in an individual. In specific cases, an inhibitor of PKR is provided to the individual such that cognition is enhanced thereby, including by enhancing memory, for example. Kits are encompassed in certain embodiments.
    Type: Application
    Filed: November 29, 2012
    Publication date: November 13, 2014
    Inventors: Mauro Costa-Mattioli, Ping Jun Zhu, Jeremy A. May
  • Publication number: 20140323450
    Abstract: The instant invention describes macrocyclic compounds having therapeutic activity, and methods of treating disorders such as methods of modulating cellular proliferation processes, and methods of treating disease, disorders, and symptoms thereof.
    Type: Application
    Filed: December 7, 2012
    Publication date: October 30, 2014
    Applicant: University of Florida Research Founation
    Inventors: Hendrik Luesch, Brian K. Law
  • Patent number: 8865700
    Abstract: Methods for preventing, ameliorating, or reducing dermatological signs of aging are provided which employ cosmetic composition comprising novel active agents that enhance collagen production in the skin.
    Type: Grant
    Filed: December 20, 2012
    Date of Patent: October 21, 2014
    Assignee: Avon Products, Inc.
    Inventors: Uma Santhanam, Permanan Raaj Khusial
  • Patent number: 8865713
    Abstract: The present invention is directed to benzoimidazole compounds of the formula: and enantiomers, diastereomers, racemates, and pharmaceutically acceptable salts thereof. Compounds of the present invention are useful in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions modulated by prolyl hydroxylase activity.
    Type: Grant
    Filed: September 3, 2013
    Date of Patent: October 21, 2014
    Assignee: Janssen Pharmaceutica NV
    Inventors: Frances Meredith Hocutt, Barry Eastman Leonard, Jr., Hillary M. Peltier, Victor K. Phuong, Michael H. Rabinowitz, Mark D. Rosen, Kyle T. Tarantino, Hariharan Venkatesan, Lucy Xiumin Zhao
  • Patent number: 8841333
    Abstract: The present invention relates to methods of treating subjects suffering from nephrolithiasis by administering to a subject in need of treatment thereof a therapeutically effective amount of at least one xanthine oxidoreductase inhibiting compound or salt thereof.
    Type: Grant
    Filed: May 8, 2006
    Date of Patent: September 23, 2014
    Assignee: Takeda Pharmaceuticals U.S.A., Inc.
    Inventor: Nancy Joseph-Ridge
  • Publication number: 20140256722
    Abstract: The present invention is directed to benzoimidazole compounds of the formula: and enantiomers, diastereomers, racemates, and pharmaceutically acceptable salts thereof. Compounds of the present invention are useful in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions modulated by prolyl hydroxylase activity.
    Type: Application
    Filed: May 20, 2014
    Publication date: September 11, 2014
    Applicant: Janssen Pharmaceutica NV
    Inventors: Frances Meredith HOCUTT, Barry Eastman Leonard, JR., Hillary M. Peltier, Victor K. Phuong, Michael H. Rabinowitz, Mark D. Rosen, Kyle T. Tarantino, Hariharan Venkatesan, Lucy Xiumin Zhao
  • Patent number: 8822698
    Abstract: Novel amino acids derivatives, in particular some amino acid amides derivatives, their process of preparation and their use for inhibiting Met-triggered disorders, in particular cancer.
    Type: Grant
    Filed: November 28, 2012
    Date of Patent: September 2, 2014
    Assignees: Universite d'Aix-Marseille, Universite de Lorraine, Oreste Piccolo Studio di Consulenza Scientifica, Universitat de Barcelona, Centre National de la Recherche Scientifique (C.N.R.S.)
    Inventors: Flavio Maina, Rosanna Dono, Oreste Piccolo, Daniele Passarella, Francesco Colombo, Joan Bosch, Bernard Maigret, Vincent Leroux
  • Publication number: 20140227320
    Abstract: Disclosed herein are compounds and related compositions for the treatment of viral infection, including RNA viral infection, and compounds that can modulate the RIG-I pathway in vertebrate cells, including compounds that can activate the RIG-I pathway.
    Type: Application
    Filed: September 27, 2012
    Publication date: August 14, 2014
    Inventors: Shawn P. Iadonato, Kristin Bedard, Myra Wang Imanaka, Kerry W. Fowler
  • Patent number: 8779154
    Abstract: The invention relates to certain fused ring compounds, or pharmaceutically acceptable salts, solvates, clathrates, or prodrugs thereof, that are useful as immunosuppressive agents and for treating and preventing inflammatory conditions, allergic disorders, and immune disorders.
    Type: Grant
    Filed: September 25, 2007
    Date of Patent: July 15, 2014
    Inventors: Qinglin Che, Nha Huu Vo, Shoujun Chen
  • Patent number: 8759345
    Abstract: The present invention is directed to benzoimidazole compounds of the formula (1) and enantiomers, diastereomers, racemates, and pharmaceutically acceptable salts thereof. Compounds of the present invention are useful in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions modulated by prolyl hydroxylase activity.
    Type: Grant
    Filed: April 28, 2009
    Date of Patent: June 24, 2014
    Assignee: Janssen Pharmaceutica NV
    Inventors: Frances Meredith Hocutt, Barry Eastman Leonard, Jr., Hillary M Peltier, Victor K. Phuong, Michael H. Rabinowitz, Mark D Rosen, Kyle T. Tarantino, Hariharan Venkatesan, Lucy Xiumin Zhao
  • Patent number: 8748429
    Abstract: The disclosure generally relates to the novel compounds of formula I, including pharmaceutically acceptable salts, which are CGRP receptor antagonists. The disclosure also relates to pharmaceutical compositions and methods for using the compounds in the treatment of CGRP related disorders including migraine and other headaches, neurogenic vasodilation, neurogenic inflammation, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases such as asthma, and chronic obstructive pulmonary disease (COPD).
    Type: Grant
    Filed: April 4, 2012
    Date of Patent: June 10, 2014
    Assignee: Bristol-Myers Squibb Company
    Inventors: Guanglin Luo, Gene M. Dubowchik, John E. Macor, Ling Chen
  • Patent number: 8748464
    Abstract: The present disclosure provides a method of increasing an immune response in an individual, the method involving administering to an individual in need thereof an inhibitor of SIRT1. The present disclosure provides a method of reducing an immune response, e.g., to treat chronic immune hyperactivity, the method generally involving administering to an individual in need thereof an activator of SIRT1. The present disclosure provides a method of modulating activation and differentiation of CD4+ T cells.
    Type: Grant
    Filed: July 16, 2010
    Date of Patent: June 10, 2014
    Assignee: The J. David Gladstone Institutes
    Inventors: Eric M. Verdin, Melanie Ott, Hye-Sook Kwon, Hyungwook Lim
  • Publication number: 20140135308
    Abstract: Benzoxepin compounds of Formula I, and including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, wherein: Z1 is CR1 or N; Z2 is CR2 or N; Z3 is CR3 or N; Z4 is CR4 or N; and where (i) X1 is N and X2 is S, (ii) X1 is S and X2 is N, (iii) X1 is CR7 and X2 is S, (iv) X1 is S and X2 is CR7; (v) X1 is NR8 and X2 is N, (vi) X1 is N and X2 is NR8, (vii) X1 is CR7 and X2 is O, (viii) X1 is O and X2 is CR7, (ix) X1 is CR7 and X2 is C(R7)2, (x) X1 is C(R7)2 and X2 is CR7; (xi) X1 is N and X2 is O, or (xii) X1 is O and X2 is N, are useful for inhibiting lipid kinases including p110 alpha and other isoforms of PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
    Type: Application
    Filed: January 23, 2014
    Publication date: May 15, 2014
    Applicant: Genentech, Inc.
    Inventors: Nicole Blaquiere, Steven Do, Danette Dudley, Adrian Folkes, Richard Goldsmith, Robert Heald, Timothy Heffron, Aleksandr Kolesnikov, Chudi Ndubaku, Alan G. Olivero, Stephen Price, Steven Staben, BinQing Wei
  • Patent number: 8703962
    Abstract: The invention relates to compounds of formula I and pharmaceutically acceptable derivatives thereof, compositions comprising an effective amount of a compound of formula I or a pharmaceutically acceptable derivative thereof, and methods for treating or preventing a condition such as pain, UI, an ulcer, IBD and IBS, comprising administering to an animal in need thereof an effective amount of a compound of formula I or a pharmaceutically acceptable derivative thereof.
    Type: Grant
    Filed: October 22, 2009
    Date of Patent: April 22, 2014
    Assignee: Purdue Pharma L.P.
    Inventors: Donald J. Kyle, Laykea Tafesse
  • Publication number: 20140093449
    Abstract: Analogs of largazole are described herein. Methods of treating cancer and blood disorders using largazole and largazole analogs and pharmaceutical compositions comprising the same are additionally described herein. Methods for preparing largazole analogs are likewise described.
    Type: Application
    Filed: July 17, 2013
    Publication date: April 3, 2014
    Applicants: COLORADO STATE UNIVERSITY RESEARCH FOUNDATION, UNIVERSITY OF NOTRE DAME DU LAC, DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Robert M. Williams, James E. Bradner, Albert Bowers, Tenaya Newkirk, Olaf G. Wiest
  • Patent number: 8685661
    Abstract: A reagent for classifying and counting leukocytes containing (1) a cyanine fluorescent dye; and (2) a glycoside compound; a reagent kit containing the reagent for classifying and counting leukocytes as well as its preparation process; and a process for classifying and counting blood cells using the reagent or kit are provided. Using the reagent, kit and/or process provided, leukocytes can be classified and counted in four groups with a high degree of differentiation and a better classification among each subpopulation of leukocytes, especially in that it successfully addresses the indistinct classification between lymphocytes and monocytes and between the eosinophils and neutrophils in a scattergram.
    Type: Grant
    Filed: July 26, 2010
    Date of Patent: April 1, 2014
    Assignee: Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
    Inventors: Yang Zhao, Ting Lei, Yumei Zhao, Bing Xu
  • Publication number: 20140080825
    Abstract: The present invention relates to modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”), compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators.
    Type: Application
    Filed: August 21, 2013
    Publication date: March 20, 2014
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Sara Sabina Hadida-Ruah, Peter Diederik Jan Grootenhuis, Mark Thomas Miller, Matthew Hamilton
  • Patent number: 8658207
    Abstract: The present invention provides pharmaceutical release systems comprising an therapeutically effective amount of flibanserin and at least one pharmaceutically acceptable excipient, characterized in that said pharmaceutical release systems exhibit a pharmacokinetic profile that is characterized by an average maximum flibanserin plasma concentration Cmax lower than 300 ng/mL, preferably lower than 200 ng/mL after administration of a single dose to healthy volunteers in fasted state or directly after a meal.
    Type: Grant
    Filed: August 13, 2007
    Date of Patent: February 25, 2014
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Wolfram Eisenreich, Thomas Friedl, Florian Sommer, Nantharat Pearnchob, Karl G. Wagner
  • Publication number: 20140031400
    Abstract: The instant invention describes macrocyclic compounds having therapeutic activity, and methods of treating disorders such as cancer, tumors and cell proliferation related disorders, or affect cell differentiation, dedifferentiation or transdifferentiation.
    Type: Application
    Filed: January 22, 2013
    Publication date: January 30, 2014
    Applicant: University of Florida Research Foundation, Inc.
    Inventor: University of Florida Research Foundation, Inc.
  • Patent number: 8629159
    Abstract: The present invention relates to thiazolidinedione analogues that are useful for treating hypertension.
    Type: Grant
    Filed: September 16, 2008
    Date of Patent: January 14, 2014
    Assignee: Metabolic Solutions Development Company, LLC
    Inventors: Gerard R. Colca, Rolf F. Kletzien
  • Publication number: 20140011849
    Abstract: The present invention provides a compound represented by the formula which is useful as an agent for the prophylaxis or treatment of diseases related to the action of melatonin, or a salt thereof and the like.
    Type: Application
    Filed: September 4, 2013
    Publication date: January 9, 2014
    Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Osamu UCHIKAWA, Tatsuki KOIKE, Yasutaka HOASHI, Takafumi TAKAI
  • Publication number: 20140005193
    Abstract: The present invention is directed to benzoimidazole compounds of the formula: and enantiomers, diastereomers, racemates, and pharmaceutically acceptable salts thereof. Compounds of the present invention are useful in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions modulated by prolyl hydroxylase activity.
    Type: Application
    Filed: September 3, 2013
    Publication date: January 2, 2014
    Applicant: JANSSEN PHARMACEUTICA NV
    Inventors: Frances Meredith Hocutt, BARRY EASTMAN LEONARD, JR., HILLARY M. PELTIER, VICTOR K. PHUONG, MICHAEL H. RABINOWITZ, MARK D. ROSEN, KYLE T. TARANTINO, HARIHARAN VENKATESAN, LUCY XIUMIN ZHAO
  • Publication number: 20130338117
    Abstract: This invention provides methods of inhibiting replication of a poxvirus by contacting a poxvirus with a compound having formula I, formula XXI, formula XXXII, or formula XLI which in turn reduce, inhibit, or abrogate poxvirus DNA polymerase activity and/or its interaction with its processivity factor. Formula I, formula XXI, formula XXXII, or formula XLI can be utilized to treat humans and animals suffering from a poxvirus infection. Pharmaceutical compositions for treating poxvirus infected subjects are also provided.
    Type: Application
    Filed: August 27, 2013
    Publication date: December 19, 2013
    Applicant: The Trustees of the University of Pennsylvania
    Inventor: Robert P. RICCIARDI
  • Publication number: 20130324537
    Abstract: The present invention relates to guanidine compounds of the general formula I corresponding enantiomeric, diastereomeric and/or tautomeric forms thereof as well as pharmaceutically acceptable salts thereof. The present compound further relates to the use of guanidine compounds as binding partners for 5-HT5 receptors for the treatment of diseases which are modulated by a 5-HT5 receptor activity, in particular for the treatment of neurodegenerative and neuropsychiatric disorders as well as the associated signs, symptoms and dysfunctions.
    Type: Application
    Filed: November 21, 2012
    Publication date: December 5, 2013
    Applicants: Abbott Laboratories, Abbott GmbH & Co. KG
    Inventors: Abbott GmbH & Co. KG, Abbott Laboratories, Andrea Hager-Wernet
  • Patent number: 8598215
    Abstract: Compositions and methods are disclosed which are useful of the treatment and prevention of proliferative disorders.
    Type: Grant
    Filed: July 23, 2009
    Date of Patent: December 3, 2013
    Assignee: Bristol-Myers Squibb Company
    Inventor: Francis Y. F. Lee
  • Patent number: 8586550
    Abstract: The present invention relates to a novel compound with thiazole ring having an inhibitory activity against sodium-dependent glucose cotransporter 2 (SGLT2) being present in the intestine and kidney, and a pharmaceutical composition comprising the same as an active ingredient, which is useful for preventing or treating metabolic disorders, particularly diabetes.
    Type: Grant
    Filed: June 10, 2011
    Date of Patent: November 19, 2013
    Assignee: Green Cross Corporation
    Inventors: Jinhwa Lee, Jeongmin Kim, Suk Ho Lee, Junwon Lee, Kwang-Seop Song, Eun-Jung Park, Min Ju Kim, Hee Jeong Seo, Sung-Han Lee, Eun Jung Son, Jong Yup Kim, Suk Youn Kang, Younggyu Kong
  • Publication number: 20130296315
    Abstract: The present invention relates to the use of new and known dithiine derivatives for controlling unwanted microorganisms, more particularly phytopathogenic fungi, in crop protection, in the household and hygiene sector and in the protection of materials, and also to new dithiine derivatives, to processes for preparing them, to their use, and to crop protection compositions comprising these new dithiine derivatives.
    Type: Application
    Filed: March 11, 2013
    Publication date: November 7, 2013
    Inventor: Bayer CropScience AG
  • Patent number: 8569347
    Abstract: Compositions and methods are disclosed which are useful of the treatment and prevention of proliferative disorders.
    Type: Grant
    Filed: May 20, 2004
    Date of Patent: October 29, 2013
    Assignee: Bristol-Myers Squibb Company
    Inventor: Francis Y. F. Lee
  • Publication number: 20130281497
    Abstract: The instant invention describes macrocyclic compounds having therapeutic activity, and methods of treating disorders such as methods of modulating bone processes, and methods of treating bone-related disease, disorders, and symptoms thereof.
    Type: Application
    Filed: May 23, 2011
    Publication date: October 24, 2013
    Applicants: University of Florida Research Foundation, Inc., Korea Research Institute of Chemical Technology, Duke University
    Inventors: Hendrik Luesch, Jiyong Hong, Seong Hwan Kim
  • Patent number: 8557810
    Abstract: Compounds, compositions and methods are provided for modulating the activity of receptor kinases and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder mediated by receptor kinases.
    Type: Grant
    Filed: January 24, 2012
    Date of Patent: October 15, 2013
    Assignee: Ambit Biosciences Corporation
    Inventors: Shripad Bhagwat, Qi Chao, Robert M. Grotzfeld, Hitesh K. Patel, Kelly G. Sprankle
  • Publication number: 20130267543
    Abstract: The present invention relates to HSF activating compounds, methods for their discovery, and their research and therapeutic uses, as well as pharmaceutically acceptable salts, solvates, chelates, non-covalent complexes, prodrugs, mixtures (including both R and S enantiomeric forms and racemic mixtures thereof), and pharmaceutical Formulations thereof. In particular, the present invention provides compounds capable of facilitating HSF1 homotrimerization, and methods of using such compounds as therapeutic agents to treat a number of conditions associated with irregular HSF1 activity.
    Type: Application
    Filed: November 8, 2011
    Publication date: October 10, 2013
    Applicants: CHAPERONE THERAPEUTICS, INC., DUKE UNIVERSITY
    Inventors: Dennis J. Thiele, Daniel W. Neef, Jose S. Mendoza
  • Patent number: 8551963
    Abstract: Compounds, compositions and methods are provided for modulating the activity of receptor kinases and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder mediated by receptor kinases.
    Type: Grant
    Filed: November 5, 2009
    Date of Patent: October 8, 2013
    Assignee: Ambit Biosciences Corporation
    Inventors: Julius L. Apuy, Darren E. Insko, Joyce J. James